Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › NantHealth Signs Reseller Deal With Oncotest-Teva for GPS Cancer in Israel

NantHealth Signs Reseller Deal With Oncotest-Teva for GPS Cancer in Israel

Dec 06, 2016
|
staff reporter

NEW YORK (GenomeWeb) – NantHealth announced today that it has signed an exclusive reseller agreement with Teva Pharmaceuticals subsidiary Oncotest-Teva to distribute its GPS Cancer molecular test in Israel.

Under the terms of the deal, Oncotest-Teva will be the only distributor of GPS Cancer to clinicians in that country. Further terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

What's Popular?

In Cancer

  1. Illumina's Stock Falls 9 Percent on Grail Acquisition Rumors

  2. Bio-Techne, Qiagen Expand Partnership on Exosome Technology

  3. SVB Leerink Initiates Coverage of Natera With Outperform Rating

  4. Grail Plans Additional Liquid Biopsy Tests for Cancer Detection, Monitoring

    Premium

  5. Todos Medical, Care GB to Form JV to Commercialize Cancer Dx Platform

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.